Quintessence Biosciences, Inc.

Laura Strong

John A Kink

Tony Klink

Thomas J Burke

Peter A Leland

Mark N Shahan

Ronald Thaddeus Raines

Vladimir S Trubetskoy

Thomas J Rutkoski

The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.

Therapeutic ribonucleases

The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.

Non-natural ribonuclease conjugates as cytotoxic agents

The present invention is directed toward the delivery of toxic agents to pathogenic cells, particularly cancer cells. In some embodiments, the toxic agent is a human ribonuclease or similar agent that is toxic to cells.

Methods and compositions for the treatment of cancer

The present invention relates generally to conjugates of human ribonucleases and water-soluble polymers, compositions comprising the conjugates and methods of using the same. In particular, the present invention provides conjugates of human ribonucleases and one or more water-soluble polymer compositions (e.g., to increase serum half-life and a pharmacokinetic profile, in vivo biological activity, stability, and/or reduce host immune response to the protein in vivo) as well as methods of using the conjugates in the therapy, treatment, and/or prevention of disease (e.g., cancer).

Growing community of inventors

Stoughton, WI, United States of America

Laura Strong